Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride.
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D000505:Alopecia / Q000188:drug therapy* / Q000473:pathology; D042944:Cholestenone 5 alpha-Reductase; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D018120:Finasteride / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008914:Minoxidil / Q000008:administration & dosage / Q000627:therapeutic use*; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D014677:Pharmaceutical Vehicles; D014212:Tretinoin / Q000008:administration & dosage / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D004791:Enzyme Inhibitors; D007641:Keratolytic Agents; D014677:Pharmaceutical Vehicles; D014665:Vasodilator Agents; D014212:Tretinoin; D018120:Finasteride; D008914:Minoxidil; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase